Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite repeatedly being pressed by Sen. Bernie Sanders (I-Vt.), chair of the
Lawmakers press Novo Nordisk CEO over weight-loss drug prices
The Senate Committee on Health, Education, Labor and Pensions held a hearing on Tuesday, to discuss Novo Nordisk lowering prices for weight-loss drugs.
Novo Nordisk CEO Grilled by Congress Over Price of Ozempic
During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug
Ozempic maker's CEO grilled over price of weight loss drugs
The CEO of the company that makes Ozempic faced a Bernie Sanders-led Senate hearing on Tuesday.
Novo Nordisk CEO Faces Senate Questions Over High Prices Of Ozempic And Wegovy In US
Novo Nordisk CEO Lars Fruergaard Jorgensen testified before the Senate Health, Education, Labor and Pensions Committee hearing in
Bernie Sanders grills Novo Nordisk CEO on price of Ozempic, other weight-loss drugs
Sen. Bernie Sanders grilled Novo Nordisk's CEO Lars Jorgensen over the cost of the company's weight loss and diabetes medications, Ozempic and Wegovy.
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Evotec and Novo Nordisk in technology development partnership
(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
RFK Jr. bashes Ozempic buzz and Novo Nordisk profits
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
FiercePharma3d
Novo Nordisk scolded by UK drug marketing watchdog over sponsorship of weight loss services
Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...
Buy Rating for Novo Nordisk: Strong Product Efficacy and Promising Pipeline Underpin Growth Outlook
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Novo Nordisk (NVO – Research Report), retaining the price target of ...
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top ...